Table 1 Baseline demographics and clinical characteristics of included patients
Variable | Placebo N = 17 | AP N = 20 |
|---|---|---|
Age (years) | ||
Mean ± SD | 58.1 ± 7.0 | 59.4 ± 5.7 |
Median (range) | 57 (50–73) | 58.5 (51–70) |
Female sex, n (%) | 9 (53) | 15 (75) |
Primary progressive, n (%) | 10 (59) | 10 (50) |
Clinical progression in the year prior to enrolment, n (%) | 10 (59) | 16 (80) |
Disease duration | ||
Mean ± SD | 14.2 ± 9.6 | 14.9 ± 11.5 |
Median (range) | 11 (4–34) | 11.5 (5–45) |
EDSS | ||
Median | 6 | 6 |
Range | 2.5–7.0 | 3.5–7.0 |
9-Hole Peg Test (seconds) | ||
Median | 23.15 | 20.86 |
Range | 13.95–32.7 | 14.3–30.1 |
Timed 25-ft walk test (seconds) | ||
Median | 13.47 | 10.48 |
Range | 5.6–89 | 7.6–34.6 |
Not able to complete, n (%) | 1 (5.6) | 4 (20) |
Paced Auditory Serial Addition Test z-score | ||
Mean + SD | −1.96 ± 1.48 | −1.63 ± 1.57 |
Multiple Sclerosis Functional Composite | ||
Mean ± SD | −0.17 ± 0.59 | 0.20 ± 0.35 |
Median | −0.14 | − 0.01 |
Range | −2.23 | −0.88 |
Symbol Digit Modalities Test z-score | ||
Mean ± SD | −0.88 ± 0.99 | 0.03 ± 0.66 |
Retinal nerve fibre layer thickness (μm) | ||
Mean ± SD | 89.97 ± 15.49 | 90.28 ± 12.86 |
MRI activity (gadolinium-enhancing lesions), n (%) | 0 (0) | 0 (0) |
Normalized brain volume (mm3 ± SD) | 1,288,183 ± 86,721 | 1,311,701 ± 93,647 |
Normalized white matter volume (mm3 ± SD) | 662,732 ± 51,640 | 665,999 ± 48,708 |
Normalized grey matter volume (mm3 ± SD) | 625,451 ± 41,492 | 645,702 ± 49,755 |
Brain parenchymal fraction ± SD | 0.95 ± 0.02 | 0.95 ± 0.02 |